The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe

Amanda Mocroft; Adam Geressu; Charles Beguelin; Josep M Llibre; Jeffrey V Lazarus; Janez Tomazic; Jelena Smidt; Milosz Parczewski; Johanna Brännström; Dalibor Sedlacek; Olaf Degen; Marc van der Valk; Dzmitry Paduta; Leo Flamholc; Patrick Schmid; Chloe Orkin; Lars N Nielsen; Christian Hoffmann; Marek Beniowski; Cristiana Oprea; Josip Begovac; Lars Peters

doi:10.1097/QAD.0000000000003406

The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe

Amanda Mocroft^*, Adam Geressu, Charles Beguelin, Josep M Llibre, Jeffrey V Lazarus, Janez Tomazic, Jelena Smidt, Milosz Parczewski, Johanna Brännström, Dalibor Sedlacek, Olaf Degen, Marc van der Valk, Dzmitry Paduta, Leo Flamholc, Patrick Schmid, Chloe Orkin, Lars N Nielsen, Christian Hoffmann, Marek Beniowski, Cristiana OpreaJosip Begovac, Lars Peters

^*Corresponding author for this work

6 Citations (Scopus)

Abstract

BACKGROUND: There are limited data on end-stage liver disease (ESLD) and mortality in people with HIV (PWH) coinfected with both hepatitis B virus (HBV) and hepatitis C virus (HCV).

METHODS: All PWH aged greater than 18 under follow-up in EuroSIDA positive for HBsAg (HBV), and/or HCVRNA+, were followed from baseline (latest of 1 January 2001, EuroSIDA recruitment, known HBV/HCV status) to ESLD, death, last visit, or 31 December 2020. Follow-up while HCVRNA- was excluded. In two separate models, Poisson regression compared three groups updated over time; HIV/HBV, HIV/HCV, and HIV/HBV/HCV.

RESULTS: Among 5733 included individuals, 4476 (78.1%) had HIV/HCV, 953 (16.6%) had HIV/HBV and 304 (5.3%) had HIV/HBV/HCV. In total, 289 (5%) developed ESLD during 34 178 person-years of follow-up (PYFU), incidence 8.5/1000 PYFU [95% confidence interval (CI) 7.5-9.4] and 707 deaths occurred during 34671 PYFU (incidence 20.4/1000 PYFU; 95% CI 18.9-21.9). After adjustment, compared with those with HIV/HCV, persons with HIV/HBV had significantly lower rates of ESLD [adjusted incidence rate ratio (aIRR) 0.53; 95% CI 0.34-0.81]. Those with HIV/HBV/HCV had marginally significantly higher rates of ESLD (aIRR 1.49; 95% CI 0.98-2.26). Those under follow-up in 2014 or later had significantly lower rates of ESLD compared with 2007-2013 (aIRR 0.65; 95% CI 0.47-0.89). Differences in ESLD between the three groups were most pronounced in those aged at least 40. After adjustment, there were no significant differences in all-cause mortality across the three groups.

CONCLUSION: HIV/HBV-coinfected individuals had lower rates of ESLD and HIV/HBV/HCV had higher rates of ESLD compared with those with HIV/HCV, especially in those aged more than 40. ESLD decreased over time across all groups.

CLINICALTRIALSGOV IDENTIFIER: NCT02699736.

Original language	English
Journal	AIDS
Volume	37
Issue number	1
Pages (from-to)	91-103
Number of pages	13
ISSN	0269-9370
DOIs	https://doi.org/10.1097/QAD.0000000000003406
Publication status	Published - 1 Jan 2023

Keywords

HCVRNA
all-cause mortality
end stage liver disease
hepatitis B
hepatitis C

Access to Document

10.1097/QAD.0000000000003406

Cite this

Mocroft, A., Geressu, A., Beguelin, C., Llibre, J. M., Lazarus, J. V., Tomazic, J., Smidt, J., Parczewski, M., Brännström, J., Sedlacek, D., Degen, O., van der Valk, M., Paduta, D., Flamholc, L., Schmid, P., Orkin, C., Nielsen, L. N., Hoffmann, C., Beniowski, M., ... Peters, L. (2023). The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe. AIDS, 37(1), 91-103. https://doi.org/10.1097/QAD.0000000000003406

Mocroft, A, Geressu, A, Beguelin, C, Llibre, JM, Lazarus, JV, Tomazic, J, Smidt, J, Parczewski, M, Brännström, J, Sedlacek, D, Degen, O, van der Valk, M, Paduta, D, Flamholc, L, Schmid, P, Orkin, C, Nielsen, LN, Hoffmann, C, Beniowski, M, Oprea, C, Begovac, J & Peters, L 2023, 'The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe', AIDS, vol. 37, no. 1, pp. 91-103. https://doi.org/10.1097/QAD.0000000000003406

@article{e34d2d0ecb484d00a2c1b582453f373a,

title = "The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe",

abstract = "BACKGROUND: There are limited data on end-stage liver disease (ESLD) and mortality in people with HIV (PWH) coinfected with both hepatitis B virus (HBV) and hepatitis C virus (HCV).METHODS: All PWH aged greater than 18 under follow-up in EuroSIDA positive for HBsAg (HBV), and/or HCVRNA+, were followed from baseline (latest of 1 January 2001, EuroSIDA recruitment, known HBV/HCV status) to ESLD, death, last visit, or 31 December 2020. Follow-up while HCVRNA- was excluded. In two separate models, Poisson regression compared three groups updated over time; HIV/HBV, HIV/HCV, and HIV/HBV/HCV.RESULTS: Among 5733 included individuals, 4476 (78.1\%) had HIV/HCV, 953 (16.6\%) had HIV/HBV and 304 (5.3\%) had HIV/HBV/HCV. In total, 289 (5\%) developed ESLD during 34 178 person-years of follow-up (PYFU), incidence 8.5/1000 PYFU [95\% confidence interval (CI) 7.5-9.4] and 707 deaths occurred during 34671 PYFU (incidence 20.4/1000 PYFU; 95\% CI 18.9-21.9). After adjustment, compared with those with HIV/HCV, persons with HIV/HBV had significantly lower rates of ESLD [adjusted incidence rate ratio (aIRR) 0.53; 95\% CI 0.34-0.81]. Those with HIV/HBV/HCV had marginally significantly higher rates of ESLD (aIRR 1.49; 95\% CI 0.98-2.26). Those under follow-up in 2014 or later had significantly lower rates of ESLD compared with 2007-2013 (aIRR 0.65; 95\% CI 0.47-0.89). Differences in ESLD between the three groups were most pronounced in those aged at least 40. After adjustment, there were no significant differences in all-cause mortality across the three groups.CONCLUSION: HIV/HBV-coinfected individuals had lower rates of ESLD and HIV/HBV/HCV had higher rates of ESLD compared with those with HIV/HCV, especially in those aged more than 40. ESLD decreased over time across all groups.CLINICALTRIALSGOV IDENTIFIER: NCT02699736.",

keywords = "HCVRNA, all-cause mortality, end stage liver disease, hepatitis B, hepatitis C",

author = "Amanda Mocroft and Adam Geressu and Charles Beguelin and Llibre, \{Josep M\} and Lazarus, \{Jeffrey V\} and Janez Tomazic and Jelena Smidt and Milosz Parczewski and Johanna Br{\"a}nnstr{\"o}m and Dalibor Sedlacek and Olaf Degen and \{van der Valk\}, Marc and Dzmitry Paduta and Leo Flamholc and Patrick Schmid and Chloe Orkin and Nielsen, \{Lars N\} and Christian Hoffmann and Marek Beniowski and Cristiana Oprea and Josip Begovac and Lars Peters",

year = "2023",

month = jan,

day = "1",

doi = "10.1097/QAD.0000000000003406",

language = "English",

volume = "37",

pages = "91--103",

journal = "AIDS",

issn = "0269-9370",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe

AU - Mocroft, Amanda

AU - Geressu, Adam

AU - Beguelin, Charles

AU - Llibre, Josep M

AU - Lazarus, Jeffrey V

AU - Tomazic, Janez

AU - Smidt, Jelena

AU - Parczewski, Milosz

AU - Brännström, Johanna

AU - Sedlacek, Dalibor

AU - Degen, Olaf

AU - van der Valk, Marc

AU - Paduta, Dzmitry

AU - Flamholc, Leo

AU - Schmid, Patrick

AU - Orkin, Chloe

AU - Nielsen, Lars N

AU - Hoffmann, Christian

AU - Beniowski, Marek

AU - Oprea, Cristiana

AU - Begovac, Josip

AU - Peters, Lars

PY - 2023/1/1

Y1 - 2023/1/1

N2 - BACKGROUND: There are limited data on end-stage liver disease (ESLD) and mortality in people with HIV (PWH) coinfected with both hepatitis B virus (HBV) and hepatitis C virus (HCV).METHODS: All PWH aged greater than 18 under follow-up in EuroSIDA positive for HBsAg (HBV), and/or HCVRNA+, were followed from baseline (latest of 1 January 2001, EuroSIDA recruitment, known HBV/HCV status) to ESLD, death, last visit, or 31 December 2020. Follow-up while HCVRNA- was excluded. In two separate models, Poisson regression compared three groups updated over time; HIV/HBV, HIV/HCV, and HIV/HBV/HCV.RESULTS: Among 5733 included individuals, 4476 (78.1%) had HIV/HCV, 953 (16.6%) had HIV/HBV and 304 (5.3%) had HIV/HBV/HCV. In total, 289 (5%) developed ESLD during 34 178 person-years of follow-up (PYFU), incidence 8.5/1000 PYFU [95% confidence interval (CI) 7.5-9.4] and 707 deaths occurred during 34671 PYFU (incidence 20.4/1000 PYFU; 95% CI 18.9-21.9). After adjustment, compared with those with HIV/HCV, persons with HIV/HBV had significantly lower rates of ESLD [adjusted incidence rate ratio (aIRR) 0.53; 95% CI 0.34-0.81]. Those with HIV/HBV/HCV had marginally significantly higher rates of ESLD (aIRR 1.49; 95% CI 0.98-2.26). Those under follow-up in 2014 or later had significantly lower rates of ESLD compared with 2007-2013 (aIRR 0.65; 95% CI 0.47-0.89). Differences in ESLD between the three groups were most pronounced in those aged at least 40. After adjustment, there were no significant differences in all-cause mortality across the three groups.CONCLUSION: HIV/HBV-coinfected individuals had lower rates of ESLD and HIV/HBV/HCV had higher rates of ESLD compared with those with HIV/HCV, especially in those aged more than 40. ESLD decreased over time across all groups.CLINICALTRIALSGOV IDENTIFIER: NCT02699736.

AB - BACKGROUND: There are limited data on end-stage liver disease (ESLD) and mortality in people with HIV (PWH) coinfected with both hepatitis B virus (HBV) and hepatitis C virus (HCV).METHODS: All PWH aged greater than 18 under follow-up in EuroSIDA positive for HBsAg (HBV), and/or HCVRNA+, were followed from baseline (latest of 1 January 2001, EuroSIDA recruitment, known HBV/HCV status) to ESLD, death, last visit, or 31 December 2020. Follow-up while HCVRNA- was excluded. In two separate models, Poisson regression compared three groups updated over time; HIV/HBV, HIV/HCV, and HIV/HBV/HCV.RESULTS: Among 5733 included individuals, 4476 (78.1%) had HIV/HCV, 953 (16.6%) had HIV/HBV and 304 (5.3%) had HIV/HBV/HCV. In total, 289 (5%) developed ESLD during 34 178 person-years of follow-up (PYFU), incidence 8.5/1000 PYFU [95% confidence interval (CI) 7.5-9.4] and 707 deaths occurred during 34671 PYFU (incidence 20.4/1000 PYFU; 95% CI 18.9-21.9). After adjustment, compared with those with HIV/HCV, persons with HIV/HBV had significantly lower rates of ESLD [adjusted incidence rate ratio (aIRR) 0.53; 95% CI 0.34-0.81]. Those with HIV/HBV/HCV had marginally significantly higher rates of ESLD (aIRR 1.49; 95% CI 0.98-2.26). Those under follow-up in 2014 or later had significantly lower rates of ESLD compared with 2007-2013 (aIRR 0.65; 95% CI 0.47-0.89). Differences in ESLD between the three groups were most pronounced in those aged at least 40. After adjustment, there were no significant differences in all-cause mortality across the three groups.CONCLUSION: HIV/HBV-coinfected individuals had lower rates of ESLD and HIV/HBV/HCV had higher rates of ESLD compared with those with HIV/HCV, especially in those aged more than 40. ESLD decreased over time across all groups.CLINICALTRIALSGOV IDENTIFIER: NCT02699736.

KW - HCVRNA

KW - all-cause mortality

KW - end stage liver disease

KW - hepatitis B

KW - hepatitis C

UR - https://www.scopus.com/pages/publications/85143561073

U2 - 10.1097/QAD.0000000000003406

DO - 10.1097/QAD.0000000000003406

M3 - Journal article

C2 - 36476454

SN - 0269-9370

VL - 37

SP - 91

EP - 103

JO - AIDS

JF - AIDS

IS - 1

ER -

The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this